Results 291 to 300 of about 106,395 (322)
Some of the next articles are maybe not open access.
2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
Michael J. Gresser, Alan Nies
openaire +3 more sources
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
Michael J. Gresser, Alan Nies
openaire +3 more sources
Cyclooxygenase-2 inhibitors in colorectal cancer
Seminars in Oncology, 2003Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors ...
Jan Stoehlmacher, Heinz-Josef Lenz
openaire +2 more sources
Cyclooxygenase-2 selective inhibitors and the kidney
Current Opinion in Internal Medicine, 2001Cyclooxygenases (COX) are the target of non-steroidal anti-inflammatory drugs (NSAIDs) which exert their therapeutic effect by blocking COX's capacity to metabolize arachidonate to a series of biologically active fatty acids, designated prostaglandins.
Matthew D. Breyer +2 more
openaire +4 more sources
Cyclooxygenase-2 Inhibitors in Lung Cancer
Clinical Lung Cancer, 2004Prostanoids produced by the arachidonic acid pathway play an important role in multiple stages of carcinogenesis and progression of cancer. Cyclooxygenase (COX), which exists in 2 isoforms, is the rate-limiting enzyme in the COX pathway. Cyclooxygenase-1 is constitutively expressed in normal tissues and is essential for several important physiologic ...
Sakkaraiappan Ramalingam +1 more
openaire +3 more sources
Clinical experience with cyclooxygenase-2 inhibitors
Inflammation Research, 1999Increasing amounts of experimental and clinical data support the role of selective cyclooxygenase (COX)-2 inhibition in anti-inflammatory processes and the role of COX-1 inhibition in increasing the frequency of side effects. This article reviews the regulation of COX-2 in inflammatory processes based on in vitro and in vivo work.
J. van Ryn, Michel Pairet
openaire +3 more sources
Cyclooxygenase-2 selective inhibitors
Drugs of Today, 1999The identification of two cyclooxygenase (COX) enzymes has been a tremendous advance in understanding the role of prostaglandins in inflammation and the actions of nonsteroidal antiinflammatory drugs (NSAIDs). COX-1 activity appears to be related to "constitutive" or "housekeeping" functions in the gastric mucosa, kidney and platelets.
openaire +3 more sources
Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets, 2006Non-steroidal anti-inflammatory drugs (NSAIDs) represent a clinically important class of agents. NSAIDs are commonly used in treatment of conditions such as headache, fever, inflammation and joint pain. Complications often arise from chronic use of NSAIDs.
Sheldon Chaffer +6 more
openaire +3 more sources
Efficacy of cyclooxygenase-2–specific inhibitors
The American Journal of Medicine, 2001Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The clinical efficacy of NSAIDs is primarily related to the inhibition of COX-2 activity, whereas much of the toxicity, particularly gastrointestinal toxicity, is related to COX-1 inhibition.
Grant W. Cannon, Ferdinand C. Breedveld
openaire +2 more sources
Selective cyclooxygenase-2 inhibitors
La Presse Médicale, 2005Resume Objectifs L’utilisation des inhibiteurs selectifs de la cyclo-oxygenase 2 (coxibs) est actuellement contestee, en particulier en raison des risques cardiovasculaires. Peu de travaux ont evalue leurs conditions reelles d’utilisation. Cette etude avait pour buts de mesurer l’evolution des conditions reelles d’utilisation des coxibs en France et
Guy-Robert Auleley +3 more
openaire +2 more sources
Pyridazinones as selective cyclooxygenase-2 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2003Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.
Chi-Chung Chan +13 more
openaire +5 more sources